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A B S T R A C T
Background: Adenotonsillar hypertrophy (ATH) is a frequent cause of upper airways obstructive
syndromes associated to middle ear and paranasal sinuses disorders, swallowing and voice disorders,
sleep quality disorders, and occasionally facial dysmorphisms. ATH treatment is essentially based on a
number of medical–surgical aids including nasal irrigation with topical antibiotics and corticosteroids
and/or treatment with systemic corticosteroids, immunoregulators, thermal treatments, adenotonsil-
lectomy, etc.
Objectives: The aim of the present study is to assess the efﬁcacy of Aerosal1 halotherapy in the treatment
of sub-obstructive adenotonsillar disease and correlated conditions compared to placebo treatment.
Methods: A total of 45 patients with sub-obstructive adenotonsillar hypertrophy were randomized to
receive either Aerosal1 halotherapy or placebo for 10 treatment sessions. The main outcome was a
reduction greater than or equal to 25% from the baseline of the degree of adenoid and/or tonsillar
hypertrophy.
Results: In the intention-to-treat analysis, a reduction of the degree of adenoid and/or tonsillar
hypertrophy 25% from baseline after 10 therapy sessions was found in 44.4% of the patients in the
halotherapy arm and in 22.2% of the patients in the placebo arm (P = 0.204). Among the secondary
outcomes, the reduction of hearing loss after 10 treatment sessions in the halotherapy arm was higher
than the placebo arm (P = 0.018) as well as the time-dependent analysis showed signiﬁcantly improved
peak pressure in the Aerosal1 group (P = 0.038). No side effects were reported during the trial. In
addition, the therapy was well accepted by the young patients who considered it as a time for play rather
than a therapy.
Conclusions: Aerosal1 halotherapy can be considered a viable adjunct, albeit not a replacement, to
conventional medical treatment of sub-obstructive adenotonsillar syndrome and related conditions.
Further research is however needed to improve ATH treatment.
 2013 The Authors. Published by Elsevier Ireland Ltd. 
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Symptomatic adenotonsillar hyperthrophy (ATH) is a frequent
cause of obstructive syndromes ascribable to mechanic obstruction
in the oropharynx and resulting upper aerodigestive tract encum-
brance [1]. The syndrome, which usually affects children aged 3–10
years, is characterized by middle ear, nasal passages, paranasal sinus
symptoms, voice and swallowing disorders, poor sleep quality, and
occasionally facial dysmorphisms and dental malocclusion [2–7].
ATH has a typical onset after the third year of life with
symptoms progressively worsening with a peak age incidence
between 4 and 8 years [8]. BY-NC-SA license.
Fig. 1. ‘‘Salt Clinic’’. 3D design: reception/welcome area (a); waiting room with
children’s recreation area (b); ‘‘Aerosal1’’ halotherapy room (c). ENT Care Unit (d).
Cabinet containing the Dry Salt Aerosol Generator – University General Hospital –
Bari (Italy).
Fig. 2. ‘‘Aerosal’’1 Haloterapy Salt Room where children are always highly
compliant as they consider treatment sessions as opportunities for play and
recreation. ENT Care Unit–University General Hospital – Bari (Italy).
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over the last few years thanks to technological advances in
diagnostic criteria speciﬁcity that once used to rely almost
exclusively on rather empirical and vague clinical parameters
[9,10]. As a result, it has been possible to deﬁne a more accurate
nosologic picture of ATH which has allowed for a more targeted
therapeutic strategy essentially based on the use of several
therapeutic aids (topical antibiotics and corticosteroids to clear
nasal passages and/or systemic corticosteroids, etc.) [11–19]. In
this connection, in the past few years several investigators have
studied the beneﬁcial effects of salt (halotherapy from the Greek
word for salt, halos) on a number of respiratory system conditions
(rhinosinusitis, allergic rhinitis, otitis, bronchitis, and asthma) [20–
23] as well as on some dermatological pathologies (atopic
dermatitis and psoriasis) [24–26]. Halotherapy is based on a
non pharmacological approach as it relies on the release of
micronized medical sodium chloride into an indoor climate-
controlled environment. The release is meant to recreate the
conditions occurring in nature in salt mines and caves. Occasion-
ally a small amount of micronized iodine is added to mimic the
experience of being on a real naturally occurring seashore. Salt
therapy has been practised in old salt mines of Central and Eastern
Europe for centuries where it is still common being considered a
full-ﬂedged medical treatment.
The aim of the present study was to assess the efﬁcacy of
Aerosal1 in the treatment of sub-obstructive adenotonsillar
hypertrophy and correlated disease versus placebo treatment.
2. Materials and methods
2.1. Patients
Patients were recruited from the Department of Otolaryngology
(ENT) of Bari University General Hospital after approval had been
obtained by the institutional ethics committee. Inclusion criteria
were as follows: age range: 4–12 years; genders: both; pathology:
sub-obstructive adenoid hypertrophy lasting from at least six
months and associated with sleep-disordered breathing (respira-
tory pauses or sleep apnea) and/or recurrent serous otitis media;
suspension for over 3 months from the start of the study of any
immunosuppressive treatments (cyclosporin and systemic ster-
oids). Exclusion criteria: patients with acute bronchopulmonary
disease, tuberculosis, severe hypertension, hyperthyroidism,
cancer (chemotherapy), intoxication, heart failure, bronchial
asthma or iodine allergy. Patients were still allowed to use topical
therapy with nasal washings and topical steroids.
2.2. Technical speciﬁcations of salt room ‘‘Aerosal1’’
2.2.1. Salt room
Both walls and ceiling of the multilayer sea wood salt room
(2.30 mt.  2.90 mt.  2.20 mt.) are completely covered with ESCO
(European Salt Company) type certiﬁed-origin iodized rock salt.
The ﬂoor, which is also made of multilayer sea wood, is covered
with about 500 kg of RESIMAX type certiﬁed-origin rock salt
(Figs. 1 and 2).
The room environment is not contaminated with pathogenic
microorganisms (as certiﬁed by SAS 901measurements). Patients
can settle into comfortable chairs inside the room where the dry
salt aerosol is blown through a PVC pipe (described below). A
centrifugal extractor fan (air ﬂow rate 90 m3/h), placed on the side
opposite to the PVC pipe ensures a number of complete changes of
air in full compliance with requirements in terms of CO2 ppm
values, i.e. <750 ppm. Also temperature and humidity are kept at
constant values ranging between 20 8C and 24 8C and 44% and 60%,
respectively (TESTO 435-41 Digital Multimeter measurements).2.2.2. Dry salt aerosol generator
The dry salt aerosol generator is encased in a cabinet placed
outside of, albeit contiguous to, the salt room (Fig. 1d). A standard
amount of NaCl (salt sachet) is fed into the dry salt aerosol
generator to be blown into the salt room in the form of aerosol
through a PVC (polyvinyl chloride) connector. The size of NaCl,
micronized particles ranges from 0.23 to 20 mm (data collected by
portable laser aerosol spectrometer Model 1.109 with GRIMM1
technology). Particle density ranges from 20 to 35 mg/m3 and is
kept constant over time thanks to an electronic system.
2.2.3. Salt sachet: salt features
The salt sachet contains 30 g of NaCl, 20 g of micronized RG
(Reagent Grade) salt (according to Ph Eur Current Edition), and 10 g
of non micronized ESCO iodized feed salt to prevent aggregation
and keep an appropriate level of iodine exposure.
2.3. Clinical and instrumental evaluation
After collection of medical history, all the patients underwent
clinical and instrumental exams as follows: ENT visit with
inspection of the oropharyngeal tract and tonsillar hypertrophy
staging (08–48) [27], ﬂexible ﬁberscope nasal endoscopy (ENT 2000
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degree of adenoidal hypertrophy [10]. Pure tone audiometry was
performed in a sound-proofed cabin using pure tones (250 ms
duration, 25 ms rise/fall time, 50% duty cycle) at octave frequencies
from 125 Hz to 8000 Hz with a maximum intensity of 120 dB SPL
with an Amplaid 309 clinical audiometer (Amplaid, Milan, Italy).
Tympanometric measurements were performed using a 220 Hz
probe tone with an Amplaid 770 clinical tympanometer (Amplaid,
Milan, Italy). Air conduction pure tone average was obtained by the
mean of thresholds at 0.5, 1, 2 and 4 kHz. Tympanograms were
classiﬁed according to Jerger in types A, B and C [28]. Nasal
cytology was performed by anterior rhinoscopy, using a nasal
speculum and good lighting. Scrapings of the nasal mucosa were
collected from the middle portion of the inferior turbinate, using a
Rhino-Probe1 [29]. Samples were placed on a glass slide, ﬁxed by
air drying and then stained with the May-Grunwald Giemsa (MGG)
method (Carlo Erba1, Milan, Italy) [30]. Cell counts, bacterial and
fungal analysis were carried out by a semi-quantitative grading, as
proposed by Meltzer and Jalowayski [31]. The semiquantitative
evaluation of the bioﬁlms [32] was performed by counting the
number of infectious spots (ISs) in 50 microscopic ﬁelds, always at
a 1000 magniﬁcation (oil immersion). Sleep evaluation was
carried out overnight by means of wrist-worn pulse oximeters
Wrist 0x2
TM Model 3150. The parameters studied were: basal
SpO2%; event data index (adjusted index, 1 h–1) and time (%) with
SpO2 value below 95%. It was decided to use pulse oximetry [33]
instead of ‘‘gold standard’’ polysomnography [34] to study
patients’ sleep patterns as the former makes overnight studies
easier for patients at home (the protocol envisaged three such
studies in three months, two of them with only a 15-day interval).
In addition, important guidelines [35,36] do indicate pulse
oximetry as a method with a high positive predictive value of
OSASs (97%) [37].
2.4. Study design
After having given their written informed consent all the
eligible patients were randomized on a 3:2 basis to receive either
Aerosal1 or placebo. Central stratiﬁed blocked randomization
using telephone was adopted with patients, investigators and
outcomes assessor being all blinded to randomization rules.
Aerosal1 treatment consisted of 10 daily sessions (5 sessions for
week) of micronized iodized salt (sodium chloride) – with the
addition of iodine – inhalation in a chamber reproducing the
microclimate of a natural salt cave. Each daily session lasted
30 min. Treatment with placebo comparator was performed in the
same way as halotherapy but with no salt release in the room. All
patients underwent a complete clinical evaluation at baseline, at
the end of therapy period (10 sessions) and 3 months after the end
of treatment (follow-up).
2.5. Outcome measures
The primary outcome measure, evaluated both after 10 sessions
of therapy and at the 3-month follow-up, was an adenoid and/or
tonsillar hypertrophy reduction 25% from baseline as assessed by
the physician on a standardized four-point rating scale. Secondary
outcome measures included instrumental assessments: any
reductions in terms of adenoid and/or tonsillar hypertrophy
degree; any reductions of hearing loss 10 dB of the 4-frequency
(0.5, 1, 2 and 4 kHz) pure tone average, as well as any other
signiﬁcant gain; any improvements in of tympanometric values,
i.e. transition from type B curve to type C/A curve or from type C
curve to type A curve for both sides; any change in tympanogram
peak pressure (daPa); any changes in pulse-oximetric values
(increase in SpO2% mean levels, reduction of the event data index(adjusted index, 1 h–1), reduction of sleep time percentage with
SpO2 levels <95%; any reductions of the main inﬂammatory
immune cells (neutrophils, eosinophils, and mast cells) as assessed
by nasal cytology. The number of side effects reported either
during treatment period or after the end of treatment, if suspected
to be related with this latter, was also included in secondary
outcome measures.
2.6. Statistical analysis
Data were presented as medians with ranges and/or inter-
quartile ranges (IQRs), or numbers with percentages. Baseline
variables and changes in outcomes were compared between
groups by using the Mann–Whitney U test for continuous data and
Fisher’s exact test for categorical ones. Overall time-dependent
variations in primary and secondary outcomes were evaluated by
Friedman’s test for repeated measures with Page’s test for trend in
time variations. An intention-to-treat approach was adopted in
primary analyses. This approach considered patients withdrawn
prematurely from the study as treatment failures in the two study
arms. Intention-to-treat analysis was then complemented by per-
protocol analyses which considered only those patients who had
completed the study period. In the study design phase it had been
calculated that a total of 64 patients would be needed for the study
to have a 40% success rate in terms of primary outcome in the
halotherapy group as against 10% in the placebo group (a = 0.05,
b = 0.20). Statistical analysis was carried out by using MATLAB
software (MathWorks, Natick, MA, USA). Two-sided P-values
<0.05 were considered to indicate statistical signiﬁcance in all
tests.
3. Results
Between February 2012 and March 2012, 49 patients were
screened, 45 of whom (24 boys and 21 girls, average age 6 years)
underwent randomization. The reason for exclusion was age
outside the study inclusion criteria age range (n = 4). Recruitment
halted prematurely due to technical and legal issues related to the
certiﬁcation of the device. The baseline characteristics of
randomized patients in the two arms of the study are given in
Table 1. One patient, randomized to the placebo group, withdrew
after the ﬁrst week of treatment for an episode of acute tonsillitis
requiring antibiotic treatment, and one patient, randomized to the
Aerosal1 arm, withdrew during the follow-up period for exacer-
bation of upper airways symptoms. Both arms were matched in
baseline characteristics (data not shown).
3.1. Effectiveness
Fig. 3 shows the distribution of variations of measurements
from baseline in both arms after 10 treatment sessions in terms of
(i) reduction of the degree of adenoid and/or tonsillar hypertrophy;
(ii) reduction of hearing loss and (iii) tympanometry improvement.
All outcome measures and their departure from baseline at the end
of treatment sessions and at the 3-month follow up are reported in
Table 2. Assuming intention-to-treat analysis as a reference, a
reduction of the degree of adenoid and/or tonsillar hypertrophy
25% from baseline after 10 therapy sessions was found in 44.4% of
the patients in the halotherapy arm and in 22.2% of the patients in
the placebo arm (P = 0.204). These results increased to 59.3% and
38.9%, respectively at the 3-month follow up (P = 0.231). Other
substantial changes in adenoid or tonsillar hypertrophy were not
found to have a statistical signiﬁcance at any other point in time.
Among secondary outcomes hearing loss reduction was found
to be signiﬁcant (P = 0.018) after 10 treatment sessions in the
halotherapy arm compared to the placebo arm, even though the
Table 1
Baseline characteristics of randomized patients.
Aerosal (N = 27) Placebo (N = 18)
N (%) Median (IQR) Range N (%) Median (IQR) Range
Gender (male/female) 14 (51.9) 10 (55.6)
Age 6 (4) 4–12 4.5 (2) 4–10
Weight (kg) 25 (13.5) 15–56 20 (5.5) 14–41
Height (cm) 120 (24.2) 97–160 110 (10) 95–131
BMI (kg/m2) 17.4 (2.3) 14.3–25.5 16.9 (3.5) 11.6–23.9
ATH age at onset (years) 3 (2.5) 0–7 2 (1) 1–6
ATH duration (years) 3 (5.2) 1–9 2 (1) 1–5
ATH familiarity 13 (48.2) 6 (33.3)
Previous topical treatments 19 (70.4) 13 (72.2)
Previous systemic treatments 21 (77.8) 10 (55.6)
Previous ENT pathologies 22 (81.5) 14 (77.8)
Current topical treatments 5 (18.5) 4 (22.2)
Adenoid hypertrophy degree 3 (0) 3–4 3 (0) 2–4
Tonsillar hypertrophy degree 3 (0.8) 1–4 3 (1) 1–4
Nasal cytology
Neutrophils (any) 17 (63.0) 11 (61.1)
Eosinophils (any) 9 (33.3) 2 (11.1)
Mast cells (any) 3 (11.1) 1 (5.6)
Audiometry (dB)a 17.5 (19.4) 10–40 15 (25) 10–45
Tympanometry (right)
Type A curve 10 (37.0) 4 (22.2)
Type B curve 12 (44.4) 7 (38.9)
Type C curve 5 (18.5) 7 (38.9)
Tympanometry (left)
Type A curve 6 (22.2) 5 (27.8)
Type B curve 18 (66.7) 8 (44.4)
Type C curve 3 (11.1) 5 (27.8)
Tympanometric peak, right (daPa) 168 (126) 0–302 214 (123.8) 0–296
Tympanometric peak, left (daPa) 223.5 (124) 0–304 240 (133.5) 28–300
Pulse-oximetry indexes
Mean SpO2% levels 96 (1.6) 91.4–97.6 96.1 (2.2) 89.3–97.5
Apnea events (1 h–1) 1.2 (4.1) 0–24.5 1 (1.4) 0–9
Sleep time % with SpO2 <95% 11.4 (25.7) 0.1–95.9 8.5 (41.5) 0–87.6
ATH, adenotonsillar hypertrophy; ENT, otolaryngology; IQR, interquartile range; range = Min  Max. There were no signiﬁcant differences in baseline characteristics between
the two arms of the study.
a Average audiometry (left/right) evaluated at the frequencies of the tone range (0.5, 1, 2, 4 kHz).
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follow up (P = 0.107). The overall time-dependent analysis of
variations showed a signiﬁcant difference between the two arms
for hearing loss reduction with a signiﬁcant decreasing trendFig. 3. Distribution of study arms after 10 treatment sessions from baseline
according to reduction of adenoid and/or tonsillar hypertrophy degree, hearing loss
reduction and tympanometry improvement.(P = 0.010) in the treatment arm, while no signiﬁcant trend was
observed in the placebo arm (P = 0.165).
The analysis of the tympanograms showed that after 10
treatments tympanogram type improved in 29.6% of the patients
in the Aerosal1 arm compared to 5.6% of patients in the placebo
arm (P = 0.064). No difference was however observed between the
two arms at the 3-month follow up. Also in this case the time-
dependent analysis showed signiﬁcantly improved tympanogram
in the Aerosal1 group compared to the placebo group on both sides
(P = 0.002). A signiﬁcant trend was observed for both sides in the
treatment arm (P = 0.005 for the right side and P < 0.001 for the left
side), while in the placebo arm a signiﬁcant improvement was
observed only on the left side (P = 0.015). The analysis of the peak
compliance showed that even if at T1 and T2 there were no
signiﬁcant differences between the two groups in terms of peak
changes, the time-dependent analysis showed signiﬁcantly
improved peak pressure in the Aerosal1 group compared to the
placebo group on both sides (P = 0.038).
The other secondary outcomes did not exhibit major differences
between the two arms.
In more detail, as far as nasal cytology is concerned, 37.0% of
patients in the Aerosal1 arm and 22.2% of patients in the placebo
group exhibited a reduction I50% of the principal inﬂammatory
immune cells after 10 treatment sessions (P = 0.343). These
proportions were found to be 37.0% and 33.3%, respectively at
follow up evaluation (P = 1).
Regarding pulse oximetry values, baseline SpO2 did not show
any statistically signiﬁcant variation after 10 sessions (P = 0.880),
as was the case for the other two parameters under study, i.e.
Table 2
Intention-to-treat analysis of primary and secondary outcomes at T1 (10 sessions of therapy) and T2 (3 months from the end of treatment) compared to baseline.
Aerosal (N = 27) Placebo (N = 18) P-valuea
N (%) Median (IQR) N (%) Median (IQR)
T1
Reduction of adenoid hypertrophy degree (%) 0 (25) 0 (0) 0.734
Reduction 25% 8 (29.6) 3 (16.7) 0.482
Reduction of tonsillar hypertrophy degree (%) 0 (31.2) 0 (0) 0.197
Reduction 25% 9 (33.3) 3 (16.7) 0.308
Reduction of adenoid and/or tonsillar
hypertrophy degree 25% 12 (44.4) 4 (22.2) 0.204
Hearing loss reductionb (dB) 5 (13.8) 0 (10) 0.018
Reduction 10 dB 10 (37.0) 2 (11.1) 0.086
Tympanometry improvementc 8 (29.6) 1 (5.6) 0.064
Tympanometric peak pressure change (daPa) 21.5 (79.5) 1 (74) 0.141
Nasal cytology reductiond 50% 10 (37.0) 4 (22.2) 0.343
Increase of mean SpO2% levels 0.1 (1.9) 0.1 (2.8) 0.880
Reduction of apnea events (1 h–1) 0.5 (4.9) 0 (1.4) 0.372
Reduction of sleep time % with SpO2 <95% 3.6 (14.6) 2.5 (57.4) 0.424
T2
Reduction of adenoid hypertrophy degree (%) 0 (18.8) 0 (25) 0.967
Reduction 25% 7 (25.9) 6 (33.3) 0.739
Reduction of tonsillar hypertrophy degree (%) 0 (31.2) 0 (0) 0.070
Reduction 25% 11 (40.7) 3 (16.7) 0.111
Reduction of adenoid and/or tonsillar hypertrophy degree 25% 16 (59.3) 7 (38.9) 0.231
Hearing loss reductionb (dB) 2.5 (14.4) 0 (10) 0.107
Reduction 10 dB 10 (37.0) 4 (22.2) 0.343
Tympanometry improvementc 9 (33.3) 3 (16.7) 0.308
Tympanometric peak pressure change (daPa) 60.5 (104.4) 44 (78.5) 0.509
Nasal cytology reductiond 50% 10 (37.0) 6 (33.3) 1
Increase of mean SpO2% levels 0.2 (2.2) 0.2 (2) 0.772
Reduction of apnea events (1 h–1) 0.2 (2.8) 0.9 (2.1) 0.102
Reduction of sleep time % with SpO2 <95% 0.4 (28.5) 0.3 (22.2) 0.917
IQR, interquartile range.
a Mann–Whitney U-test for continuous variables, Fisher’s exact test for categorical variables.
b Reduction of average audiometry (left/right) evaluated at the frequencies of the tone range (0.5, 1, 2, 4 kHz).
c Improvement was deﬁned as deﬁned as the passage from type B curve to type C/A curve or from type C curve to type A curve for both ears sides.
d Any reduction of principal inﬂammatory immune cells (neutrophils, eosinophils, and mast cells).
Table 3
Salt room microclimate features.
Size of iodized NaCl particles released 0.23–20 mm
Particles density 35–50 mg/m3
Air exchange 90 m3/h
CO2 ppm <750
Temperature 20–24 8C
Humidity 44–60%
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sleep time with SpO2 <95% (P = 0.424). Pulse oximetry values
remained mostly unchanged at follow up.
The results of the per-protocol analysis did conﬁrm the main
ﬁndings and were generally overlapping intention-to-treat out-
comes (data not shown).
4. Discussion
The growing prevalence of conditions (both allergic and
infectious) affecting the upper airways has stimulated a whole
series of studies on topical treatments in a view to reducing the
side effects of systemic treatments and improving clinical response
in terms of improvement of nasal symptoms [38–40].
The latest guidelines issued by EPOS 2012 [41] on obstructive
and infectious nasal sinus disease include among therapeutic aids
(antibiotics, topical steroids, and topical decongestants) also nasal
saline irrigation, thus emphasizing the crucial role of this
treatment in reducing nasal congestion and mucopurulent
discharge by a washing process that restores mucociliary clearance
and prevents both locoregional (otitis, rhinosinusitis) and distant
inﬂammation (rhinobronchial syndrome, bronchitis, pneumonia,
asthma, etc.) [42–44].
In addition, in the last few years some literature studies [20–26]
have reported a new therapeutic-preventive role for sodium
chloride in what has come to be called ‘‘halotherapy’’ and in the
applications of this latter in the different branches of medicine, in
particular respiratory and dermatological disease. As a matter of
fact, for hundreds of years salt has been recognized as an agent to
treat respiratory and skin conditions. The history of using salt caves
for healing (speleotherapy from Greek speleos = cave and therapy)different ailments by assimilating dust-like salt particles goes back
to ancient times. These caves used for therapeutic purposes are still
in use in many Central and Eastern European countries including
Austria (Solzbad-Salzetnan), Romania (Sieged), Poland (Wieliczka,
one of the UNESCO World Heritage Sites), Azerbaijan (Nakhiche-
van), Kirgizia (Chon-Tous), Russia (Berezniki-Pern), and Ukraine
(Solotvino-Carpathians e Artiomovsk-Donietsk).
The possibility of recreating the microclimate (Table 3) of these
caves in a room has given a new impulse to studies and research
efforts on the potential therapeutic effects of this treatment.
As far as the present study is concerned, the ﬁrst ﬁnding has
been the absence of adverse effects. None of the children enrolled
in the study exhibited episodes of respiratory distress (dyspnea,
bronchial hyperactivity, asthma), skin itch or eyes disorders, both
during treatment and in the hours immediately after treatment. In
addition, a high compliance to treatment has been observed as
children did not consider their HT sessions as a therapy, but rather
as a time for play or recreation as they spent their 30-min sessions
playing, watching TV (cartoons, wildlife shows, etc.) (Fig. 2). Only
two children withdrew from the study; one of them (in the placebo
arm) withdrew during the ﬁrst week of halotherapy for an episode
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follow-up period for increased adenotonsillar hypertrophy associ-
ated with sleep respiratory disorders with an indication for
adenotonsillectomy. Being speciﬁc to the natural course of the
conditions in question, these episodes have not been considered as
adverse events connected to the halotherapeutic treatment.
However the most interesting aspects emerging from the
present study have been those related to the assessment of the real
impact of halotherapy on both the lymphatic component
(adenotonsillar component) and co-morbidities, namely ear
conditions and sleep disorders. Actually, the numerous studies
conducted so far on halotherapy have mainly been focused on
lower airways conditions (cystc ﬁbrosis, bronchitis, and asthma
[21–23]).
Our study has highlighted a 25% reduction of the adenoton-
sillar tissue in 44.4% of the patients treated versus 22.2% of the
placebo controls. In our view, far from being statistically signiﬁcant
(P = 0.204), this ﬁnding has a clinical value that deserves further
study. This pattern has also been conﬁrmed by the pulse-oximetric
data that, far from being statistically signiﬁcant, have shown a
decreased event data index (adjusted index) as well as a reduction
of the sleep time percentage with SpO2 <95%. Based on our results
it is possible to calculate that approximately 140 patients (70 in
each arm) would be needed to show a signiﬁcant reduction of the
adenotonsillar tissue as expressed in the primary outcome. It is
therefore unlikely that the loss of power due to the reduced
number of patients enrolled in the study (45) compared to the
planned number (64) had a signiﬁcant impact on our ﬁndings. The
reduction of some clinical and endoscopic parameters also in the
control group should however be justiﬁed by the fact that the very
young patients actually spent their time in a ‘‘salted’’ environment
where their same manipulation of salt released microparticles of
sodium chloride available for inhalation.
Among secondary end-points, end-of-treatment improvement
of hearing loss has been found to be statistically signiﬁcant in the
halotherapy group (P = 0.018) compared to the control group. The
statistical analysis has demonstrated a signiﬁcant improvement of
both tympanogram and hearing loss in the Aerosal1 group.
The treatment of otitis media with effusion (OME) is still
controversial today. While this condition has a high likelihood of a
spontaneous recovery [45], so far no medical therapy has been
shown to be effective to treat OME, as indicated by recent reviews
[46–49]. The presence of a control group in our study does rule out
the possibility that the improvements observed are linked only to a
spontaneous recovery from the disease. Even though the
effectiveness of sodium chloride in OME treatment has never
been reported in literature studies, the potential mechanisms of
action could be ascribed to decongestion of nasal passages and
tubaric oriﬁce respiratory mucosa as well as to a restored muco-
ciliary clearance that would favor middle ear aeration-draining
mechanisms. This assumption is substantiated by literature
studies that report the efﬁcacy of those treatments targeted to
improve middle ear ventilation. Perera et al. reported some
evidence that autoinﬂation devices may be of beneﬁt in the short-
term in treating children with otitis media with effusion [50].
Similar results were reported in a group of children affected by
OME treated with swallowing and auto-inﬂation exercises,
including Valsalva maneuver [51]. Finally even if the improvement
of hearing threshold was on average of only 5 dB, it is important to
remember that the pre-treatment threshold was on average
between 15 and 17.5 dB, therefore a 5 dB change together with a
change in tympanogram is clinically relevant. A longer treatment
could however further improve the hearing thresholds.
No statistically signiﬁcant difference has been found in terms of
sleep quality and nasal immunophlogosis parameters. Recent work
on bronchial immunophlogosis conﬁrms these ﬁndings [52].5. Conclusions
Haloterapy accounts for a relatively new, completely natural
therapeutic remedy which does not call for any pharmacological
administration and is based on the healing capacities of natural salt
micronized and released into an indoor environment by means of
speciﬁc techniques. Halotherapy administered by Aerosal1 system
has been shown to have a statistically signiﬁcant effect on OME.
Aerosal1 halotherapy has also been found to be partially effective
in reducing adenotonsillar hypertrophy. The beneﬁcial effects of
the treatment in question have been shown for some ‘‘time-
dependent’’ parameters, therefore additional studies should be
conducted in a view to deﬁning treatment modalities likely to
result in a better clinical response. New double-blind, placebo-
controlled, randomized clinical studies should also be performed
on more complex conditions including asthma, cystic ﬁbrosis,
chronic pulmonary disease and dermatological conditions.
In addition to being a safe treatment, the Aerosal1 Haloterapy
system has been well accepted and tolerated by our young patients
who experienced their halotherapeutic sessions as a time for play
and recreation and not as a real medical treatment. Therefore
Aerosal1 Haloterapy might constitute a valuable adjunct (and not
a replacement) to current orthodox medical treatment of
adenotonsillar disease and correlated conditions.
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